Drugs in ATC Class A01AB

Up to Top Level ATC Classes

Up to A - Alimentary tract and metabolism

Up to A01 - STOMATOLOGICAL PREPARATIONS

Up to A01A - STOMATOLOGICAL PREPARATIONS

Drugs in ATC Class: A01AB - Antiinfectives and antiseptics for local oral treatment

Tradename	Generic Name
ESKATA	hydrogen peroxide
AVAGARD	alcohol; chlorhexidine gluconate
EXIDINE	chlorhexidine gluconate

Last updated: June 12, 2026

Market dynamics and patent landscape for ATC Class A01AB antiinfectives and antiseptics for local oral treatment

What drugs sit in ATC A01AB and who sells them?

ATC A01AB is a therapeutic bucket for antiinfectives and antiseptics used locally in the oral cavity. In practice, market shares and patent pressure are driven by a small set of active ingredients (and their dosage forms) rather than the full ATC class.

Primary commercial active ingredients commonly used in oral antiseptic/antiinfective local therapy include:

• Chlorhexidine (saliva/oral rinse and topical forms; includes salt forms such as chlorhexidine digluconate).
• Povidone-iodine (oral antiseptic formulations).
• Hydrogen peroxide and related antiseptic systems (over-the-counter antiseptics in oral care).
• Cetylpyridinium chloride (mouthwashes and lozenges).
• Benzidamine-class antiseptic/anti-inflammatory local products (some labeled for oral use; patent maps often tie to specific formulations).
• Silver-based antiseptics (where present in oral care, typically older or localized IP).

Market dynamics pattern in A01AB

• High OTC penetration for antiseptic mouthwash products reduces long-tenor patent value versus prescription-only models.
• Prescription-driven pockets exist where local oral antiinfectives target specific indications (eg, gingivitis, oral mucosal infections) and where regulatory exclusivity can be used to preserve brand positioning.
• Reformulation and delivery system IP is the main moat: flavor systems, solubilizers, stabilization, mouthfeel, sustained-release or adherence systems, and unit-dose formats.
• Country-level manufacturing and regulatory filing strategy matters more than global patent coverage due to fragmentation of oral-care product authorizations.

How strong is the patent estate in ATC A01AB versus adjacent oral antiseptics?

Patent strength in A01AB typically clusters around three layers:

1. Active ingredient patents: often old and expiring or already expired for mainstream antiseptics (chlorhexidine, povidone-iodine, cetylpyridinium chloride).
2. Salt forms and compositions: newer filings can extend protection for particular salt forms, concentrations, and stabilized solutions.
3. Formulation and method patents: the most common enforceable IP, targeting:
   • aqueous stabilization (oxidation control for peroxide systems)
   • taste masking, pH control, and viscosity/tackifier systems
   • long contact time or film-forming compositions for mucosal adherence

Business implication

• The “patent life” that matters is usually formulation-specific and often shorter than brand owners expect if generics can match the composition outside the narrow claim set.

Which patents protect chlorhexidine-based oral antiseptics and how many are still enforceable?

Chlorhexidine remains one of the dominant actives for local oral antisepsis. Patent coverage is usually not tied to the molecule itself but to:

• stabilized compositions (including preservatives, chelators, buffers)
• unit-dose delivery formats
• specific concentration and pH windows
• processes for manufacturing stable solutions

Patent landscape characteristics

• Claim sets tend to be narrow around concentration ranges and excipient systems.
• Many “families” show multiple continuation filings (composition and process variants) across jurisdictions.
• Enforcement often focuses on formulation look-alikes, especially when a generic product copies the same flavor/buffer/stabilization system.

Risk for generic entrants

• If Orange Book-style exclusivity does not exist (common for OTC antiseptics), the legal entry route is driven by composition patent infringement and trademark/branding, not Hatch-Waxman paragraph IV.

What formulations are protected by povidone-iodine and cetylpyridinium chloride oral products?

For povidone-iodine and cetylpyridinium chloride, enforceable IP is usually dominated by:

• complexation/iodine availability control (for povidone-iodine)
• stabilized solubilization in mouthwash bases
• taste and mouthfeel tuning
• dose and retention enhancement in sprays, gels, or lozenges

Key commercial dynamic

• Brand differentiation often persists even after composition patents expire because of consumer habit and channel strategy. Patent value in these actives can decline faster than brand equity value.

When does patent exclusivity lose effect for A01AB oral antiseptics?

A01AB exclusivity timing depends on whether a product is treated as a systemic drug with regulatory listing for exclusivity or as a low-risk local OTC authorization.

Typical timing pattern for enforceable IP in oral antiseptics

• Active ingredient families: frequently long expired or near expiry in most developed markets.
• Composition/formulation families: last protection is often within the next decade for newer “stabilized” and “delivery” families, but varies by jurisdiction.
• Process patents: often expire later than composition patents within the same family if filed with distinct priority dates and continuation structure.

Featured snippet answer

• Expect exclusivity loss to be driven by formulation patents expiring by country, not by the base active ingredient.

Do Paragraph IV challenges apply to A01AB, and how do they affect entry?

Paragraph IV challenges are tied to FDA NDA ANDA structures and Orange Book listings. Many antiseptic/oral care products in A01AB are not positioned through Hatch-Waxman in the way prescription oral antiinfectives are, so Paragraph IV prevalence is lower.

Where Orange Book listings exist for a specific product, a Paragraph IV filing introduces:

• a statutory stay (if requirements are met)
• settlement leverage where the brand trades early generic launch in exchange for payment and/or license terms

Practical litigation pattern in A01AB-like markets

• Even without Paragraph IV, entry can trigger composition patent infringement suits in court if claims cover excipient systems or stabilization methods.

What patent litigation affects local oral antiseptics?

A01AB litigation risk tends to be:

• low frequency but high impact when it targets a core formulation family
• concentrated on formulation and process claims rather than active ingredient
• often paired with injunction threats tied to “same-way” formulation copy risk

Enforcement targets

• generic or private-label oral rinses/sprays with the same concentration and base formulation
• contract manufacturers replicating stabilization recipes for multiple brands

How do patent estates differ between major oral antiseptic brands?

Differences between brand patent estates in A01AB are usually structural:

• One company may hold multiple formulation families around the same active and concentration windows.
• Another may rely more on commercialization and trademarks, with thinner IP claims.

Business outcome

• Stronger estates can delay entry for specific SKUs even when the active ingredient is off-patent, by blocking “near identical” compositions.

What is the Orange Book status of A01AB products?

Orange Book status is product-specific. A01AB includes many local oral antiseptics that may be:

• OTC and not listed
• locally authorized products with different regulatory frameworks than FDA NDA/ANDA
• FDA-listed prescription products with Orange Book entries

Featured snippet answer

• Orange Book protection for A01AB products is intermittent; it depends on whether the exact marketed product has listed patents under an FDA reference product.

How does FDA regulatory pathway influence generic risk in A01AB?

Generic risk is a function of:

• whether there is an FDA-listed reference drug with an ANDA route
• whether exclusivity is tied to 3-year/5-year exclusivity or patent listing
• whether the generic can achieve bioequivalence through formulation matching versus navigating through different regulatory statuses

In local oral antiseptics:

• systemic exposure is limited
• regulatory approval may depend more on product sameness and QC equivalence than on PK bridging
• patent claims on formulation and stabilization can still control market entry even if regulatory approval is straightforward

Which companies are challenging oral antiseptic patent estates?

Challenges typically come from:

• established generic manufacturers that enter via ANDA where listed patents exist
• OTC oral care incumbents producing private label copies
• regional generic players filing in jurisdictions with fewer enforcement resources

Litigation leverage comes from:

• the availability of design-around formulations
• the presence of “blocking” patents that claim excipient systems or processes rather than broad active ingredient use

How does A01AB compare with adjacent ATC classes for patent density and entry barriers?

Compared with systemic antiinfectives, A01AB typically has:

• lower active-ingredient patent density
• more reliance on formulation patents and manufacturing know-how
• lower likelihood of broad method-of-use blocks unless a specific therapeutic use is claimed for a prescription indication

Competitive effect

• Entry barriers can be narrower than in systemic infection categories, but formulation-specific claims can still create SKU-level exclusivity.

What generic entry risks exist for chlorhexidine and povidone-iodine mouthwashes?

Generic entrants face three main risks:

1. composition infringement: matching the claimed concentration and excipient system
2. process infringement: stabilization manufacturing steps that are part of the claims
3. data exclusivity or listed-patent status: where the product is FDA-listed and patent-protected

Design-around feasibility

• If claims are concentrated in narrow concentration and excipient ranges, redesign can work.
• If patents cover broader stabilization logic, entry delays may persist.

Geographic coverage: where are A01AB patents most likely to matter?

Patent enforcement tends to concentrate in:

• the US (if Orange Book listed patents exist)
• EU (EPO-centric families, enforcement via national courts)
• UK, Canada, Japan depending on company footprints
• large pharmaceutical markets where oral antiseptic brands invest in formulation IP

OTC and local products can still have meaningful patent coverage, but enforcement intensity is often tied to unit sales scale.

Revenue exposure: how much of brand value is tied to patents in A01AB?

Revenue exposure is usually product-SKU and geography specific:

• where formulation patents extend brand margin for a particular mouthwash/spray
• where the brand is prescription-linked with stronger regulatory listing and exclusivity

In many A01AB segments, active ingredient competition drives margin compression, so patent value is concentrated in:

• high-velocity SKUs
• formulations defended by tight claim scopes

Key Takeaways

• A01AB oral antiinfectives and antiseptics are typically dominated by chlorhexidine, povidone-iodine, and quaternary ammonium antiseptics; the base actives are often long off-patent, shifting value to formulation and process patents.
• Exclusivity loss is driven by country-specific formulation patent expirations and whether products are FDA Orange Book listed; many A01AB products do not support broad Hatch-Waxman Paragraph IV patterns.
• Litigation, where it occurs, targets narrow composition and stabilization claim coverage, creating SKU-level barriers more than category-wide barriers.
• Generic entry risk is highest when brands hold multiple formulation families that are hard to design around without changing concentration, pH, excipients, or manufacturing steps.

FAQs

1. How do formulation patents for oral chlorhexidine mouthwash typically block generic launches?
2. Which oral antiseptic patents are most likely to be enforced as process patents rather than composition patents?
3. Do OTC oral antiseptics in ATC A01AB face Orange Book-based generic entry barriers?
4. What claim elements (pH, concentration, preservatives, buffers) most often determine infringement for antiseptic mouthwash products?
5. How do patent estates for oral antiseptics differ between the US and the EU in enforcement outcomes?

References

1. World Health Organization. ATC classification system for ATC code A01AB. (Accessed via WHO ATC/DDD resources).